MEDS · Insider Trading
DataMeds AI, Inc. Common Stock
Every open-market purchase and sale reported by MEDS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-28 | Prashant Patel | Interim CFO and Director | A | +10,000 | — |
| 2024-05-28 | Surendra K Ajjarapu | Chairman and CEO | A | +10,000 | — |
| 2024-01-16 | Surendra K Ajjarapu | Chairman and CEO | A | +150,000 | — |
| 2024-01-16 | Prashant Patel | Interim CFO and Director | A | +150,000 | — |
| 2023-02-24 | Janet Huffman | CFO, PAO, PFO | A | +50,000 | — |
| 2023-01-20 | Michael L Peterson | Director | A | +100,000 | — |
| 2022-12-30 | A. Jeffrey Newell | Director | A | +79,062 | — |
| 2022-09-16 | Janet Huffman | CFO, PAO, PFO | A | +21,551 | — |
| 2022-09-16 | Donald G. Fell | Director | A | +54,525 | — |
| 2022-09-16 | Charles L Pope | Director | A | +54,525 | — |
| 2022-09-16 | Prashant Patel | President and COO | A | +8,620 | — |
| 2022-09-16 | Surendra K Ajjarapu | CEO | A | +51,724 | — |
| 2022-08-29 | Donald G. Fell | Director | Buy | +1,500 | +$1.62K |
| 2022-05-23 | Surendra K Ajjarapu | CEO | Buy | +10,000 | +$13.00K |
| 2022-05-23 | Surendra K Ajjarapu | CEO | Buy | +10,000 | +$130.00M |
| 2022-05-18 | Donald G. Fell | Director | Buy | +2,000 | +$2.52K |
| 2022-04-04 | Howard A. Doss | — | — | — | — |
| 2021-06-22 | Michael L Peterson | — | Sell | −900 | −$4.00K |
| 2021-06-04 | Christine L. Jennings | Director | A | +10,912 | +$41.25K |
| 2021-06-02 | Pamela Tenaerts | — | D | −8,041 | — |
| 2021-06-02 | Michael L Peterson | — | D | −8,041 | — |
| 2021-06-02 | Charles L Pope | Director | A | +10,912 | +$41.25K |
| 2021-05-06 | Donald G. Fell | Director | G | −2,550 | — |
| 2021-04-20 | Pamela Tenaerts | Director | A | +10,721 | +$55.00K |
| 2021-04-20 | Prashant Patel | President | Sell | −7,500 | −$32.91K |
| 2021-04-20 | Michael L Peterson | Director | MIXED | +9,821 | +$50.79K |
| 2021-04-20 | Donald G. Fell | Director | A | +10,721 | +$55.00K |
| 2021-04-15 | Donald G. Fell | Director | A | +8,987 | +$55.00K |
| 2021-04-15 | Donald G. Fell | Director | Sell | −500 | −$2.65K |
| 2021-04-15 | Donald G. Fell | Director | MIXED | +707 | +$4.18K |
| 2020-12-16 | Pamela Tenaerts | Director | Sell | −800 | −$4.24K |
| 2020-12-16 | Prashant Patel | President | Sell | −7,500 | −$39.70K |
| 2020-12-15 | Donald G. Fell | Director | Sell | −500 | −$2.65K |
| 2020-12-15 | Michael L Peterson | Director | Sell | −1,800 | −$9.46K |
| 2020-07-21 | Prashant Patel | President | Sell | −7,500 | −$40.94K |
| 2020-06-16 | Surendra K Ajjarapu | CEO | J | −201,613 | — |
| 2020-04-16 | Prashant Patel | President | A | +50,000 | +$306.00K |
| 2020-04-15 | Michael L Peterson | Director | A | +8,987 | +$55.00K |
| 2020-04-15 | Pamela Tenaerts | Director | A | +8,987 | +$55.00K |
| 2020-04-15 | Donald G. Fell | Director | A | +8,987 | +$55.00K |
| 2020-04-15 | Surendra K Ajjarapu | CEO | A | +123,504 | +$755.84K |
| 2020-04-15 | Howard A. Doss | CFO | A | +12,500 | +$76.50K |
| 2020-04-02 | Pamela Tenaerts | Director | A | +16,667 deriv. | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MEDS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.